Oryzon Genomics S.A. (BME: ORY)
Health Care · Biotechnology · ES
€2.85
+2.37% today · +8.3% 1Y
Oryzon Genomics S.A. (BME: ORY) operates in the Biotechnology industry within the Health Care sector. The company is valued at $273.08M and employs 46 people.
Over the last twelve months the share price has gained 8.3%, trading between 2.58 and 4.02.
Tweenvest scores Oryzon Genomics S.A. across four factors: quality 52/100, value 62/100, growth 49/100. Its strongest factor is value.
ORY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $273.08M
- Revenue (TTM)
- $17.60M
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- 0.44
- 52-week high
- €4.02
- 52-week low
- €2.58
- Avg volume (3M)
- —
- Shares outstanding
- 81.96M
- Employees
- 46
- Next earnings
- —
About Oryzon Genomics S.A.
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
- ISIN
- ES0167733015
- Founded
- 2000
- Listed since
- Dec 14, 2015
- Exchange
- Bolsas y Mercados Espanoles
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.